Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab

Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab

Abstract The checkpoint inhibitor nivolumab is active in patients with metastatic melanoma who have failed ipilimumab. In this phase I/II study, we assessed nivolumab's safety in 92 ipilimumab-refractory patients with unresectable stage III or IV melanoma, including those who experienced grade...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Jeffrey S. Weber, Geoffrey T. Gibney, Ragini R. Kudchadkar, Bin Yu, Pingyan Cheng, Alberto J. Martinez, Jodie Kroeger, Allison Richards, Lori McCormick, Valerie E. Moberg, Heather Cronin, Xiuhua Zhao, Michael J. Schell, Y. Ann Chen
Médium: Artigo
Jazyk:angličtina
Vydáno: 2016
On-line přístup:https://doi.org/10.1158/2326-6066.cir-15-0193
https://cancerimmunolres.aacrjournals.org/content/canimm/4/4/345.full.pdf
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Internet

https://doi.org/10.1158/2326-6066.cir-15-0193
https://cancerimmunolres.aacrjournals.org/content/canimm/4/4/345.full.pdf

Podobné jednotky